GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medizen Humancare Inc Co Ltd (XKRX:236340) » Definitions » Float Percentage Of Total Shares Outstanding

Medizen Humancare Co (XKRX:236340) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 24, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Medizen Humancare Co Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medizen Humancare Co's float shares is 0.00 Mil. Medizen Humancare Co's total shares outstanding is 3.01 Mil. Medizen Humancare Co's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medizen Humancare Co's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medizen Humancare Co's Institutional Ownership is 0.21%.


Medizen Humancare Co Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Medizen Humancare Co's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/3.01
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medizen Humancare Co Business Description

Traded in Other Exchanges
N/A
Address
Republic of Korea 223, Teheran-ro, Gangnam-gu, Seoul, KOR
Medizen Humancare Inc Co Ltd is a R&D company providing genomics involving acquisition of disease specific genome contents, identification of new drug candidate genes and development of new preventive measures.

Medizen Humancare Co Headlines

No Headlines